Predict your next investment

Venture Capital
columbusvp.com

See what CB Insights has to offer

Investments

15

Portfolio Exits

3

Funds

4

Partners & Customers

2

About Columbus Venture Partners

Columbus Venture Partner (CVP) is an independent venture capital that brings a unique approach for investing in outstanding early-stage and high growth opportunities in the life science industry in Spain. CVP portfolio is mainly invested in the Spanish market through its fund Columbus INNVIERTE Life Sciences FCR, in which the Spanish government participates through CDTI.

Columbus Venture Partners Headquarter Location

C/ Jose Abascal 58, 7D

Madrid, 28003,

Spain

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Columbus Venture Partners News

Artax Biopharma Closes USD 26M Financing Round

May 12, 2022

Artax Biopharma, a Cambridge, MA-based clinical stage biotechnology company, raised USD 26M in funding. The round was led by Eli Lilly and Company and Sound Bioventures with participation from Advent Life Sciences, Columbus Venture Partners, and Belinda Termeer and other shareholders.

Columbus Venture Partners Investments

15 Investments

Columbus Venture Partners has made 15 investments. Their latest investment was in Integra Therapeutics as part of their Seed VC - II on March 3, 2022.

CBI Logo

Columbus Venture Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/29/2022

Seed VC - II

Integra Therapeutics

$1.66M

Yes

3

1/3/2022

Series C

Artax Biopharma

$26M

No

3

7/7/2021

Series B - II

NeRRe Therapeutics

$27.6M

Yes

2

3/22/2021

Series E

Subscribe to see more

$99M

Subscribe to see more

10

2/4/2021

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/29/2022

1/3/2022

7/7/2021

3/22/2021

2/4/2021

Round

Seed VC - II

Series C

Series B - II

Series E

Series D

Company

Integra Therapeutics

Artax Biopharma

NeRRe Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$1.66M

$26M

$27.6M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

3

2

10

10

Columbus Venture Partners Portfolio Exits

3 Portfolio Exits

Columbus Venture Partners has 3 portfolio exits. Their latest portfolio exit was Sanifit on November 22, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/22/2021

Acquired

$99M

6

10/29/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/26/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/22/2021

10/29/2021

10/26/2020

Exit

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

6

10

10

Columbus Venture Partners Fund History

4 Fund Histories

Columbus Venture Partners has 4 funds, including Columbus Life Sciences Fund III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/26/2021

Columbus Life Sciences Fund III

$144.99M

2

9/23/2019

Columbus Life Science Fund II

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2016

Columbus INNVIERTE Life Sciences

Subscribe to see more

Subscribe to see more

$99M

10

Columbus Venture Partners

Subscribe to see more

Subscribe to see more

10

Closing Date

4/26/2021

9/23/2019

12/31/2016

Fund

Columbus Life Sciences Fund III

Columbus Life Science Fund II

Columbus INNVIERTE Life Sciences

Columbus Venture Partners

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$144.99M

$99M

$99M

Sources

2

10

10

10

Columbus Venture Partners Partners & Customers

2 Partners and customers

Columbus Venture Partners has 2 strategic partners and customers. Columbus Venture Partners recently partnered with AskBio on October 10, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

10/17/2017

Partner

United States

AskBio and Columbus Venture Partners Launch Gene Therapy Company Viralgen

Asklepios BioPharmaceutical , Inc. announced today the formation of Viralgen , a gene therapy joint venture with Columbus Venture Partners .

2

10/17/2017

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

10/17/2017

10/17/2017

Type

Partner

Partner

Business Partner

Country

United States

United States

News Snippet

AskBio and Columbus Venture Partners Launch Gene Therapy Company Viralgen

Asklepios BioPharmaceutical , Inc. announced today the formation of Viralgen , a gene therapy joint venture with Columbus Venture Partners .

Subscribe to see more

Subscribe to see more

Sources

2

10

Columbus Venture Partners Team

3 Team Members

Columbus Venture Partners has 3 team members, including current President, General Partner, Javier G Cogorro.

Name

Work History

Title

Status

Javier Garcia

Founder

Current

Javier G Cogorro

President, General Partner

Current

Victor Vercher

Chief Financial Officer

Former

Name

Javier Garcia

Javier G Cogorro

Victor Vercher

Work History

Title

Founder

President, General Partner

Chief Financial Officer

Status

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.